General Information of Drug (ID: DMSX5NJ)

Drug Name
RG6330 Drug Info
Synonyms GDC-6036
Indication
Disease Entry ICD 11 Status REF
Solid tumour/cancer 2A00-2F9Z Phase 1 [1]
Cross-matching ID
PubChem CID
146624881
TTD Drug ID
DMSX5NJ

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Sotorasib DMLSV74 Non-small-cell lung cancer 2C25 Approved [2]
Adagrasib DMDV4EP Non-small-cell lung cancer 2C25 Approved [3]
JDQ443 DMHI7CQ Non-small-cell lung cancer 2C25 Phase 3 [4]
LY3499446 DMA1CSR Solid tumour/cancer 2A00-2F9Z Phase 1/2 [5]
JNJ-74699157 DMY7CW1 Solid tumour/cancer 2A00-2F9Z Phase 1 [5]

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
KRAS G12C mutant (KRAS G12C) TT3LH46 RASK_HUMAN Inhibitor [1]

References

1 Clinical pipeline report, company report or official report of Roche.
2 Clinical pipeline report, company report or official report of Amgen.
3 Clinical pipeline report, company report or official report of Mirati Therapeutics.
4 Discovery, Preclinical Characterization, and Early Clinical Activity of JDQ443, a Structurally Novel, Potent, and Selective Covalent Oral Inhibitor of KRASG12C. Cancer Discov. 2022 Jun 2;12(6):1500-1517.
5 KRAS: From undruggable to a druggable Cancer Target. Cancer Treat Rev. 2020 Sep;89:102070.